Biomarin Pharmaceutical
- Market cap
- 10.69B
- P/E (TTM)i
- 145.26
- P/Bi
- 1.69
- EPSi
- 1.80
- Div yieldi
- 0.00%
- 52W posi
- 27%
Anonymous reader poll. Unscientific, not investment advice.
Shares of Biomarin Pharmaceutical closed at 55.20, down 1.81%. The company carries a market value of roughly 10.69B, the #1379 most valuable US-listed company we track. The trailing P/E of 150.87 is broadly in line with its five-year average of 155.81. Across 21 analysts the consensus rating is Buy, with an average price target of 94.89 (+72%). Against a 52-week band of 49.26-70.98, the shares are currently 27% of the way up.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 1 week.
- Recent price momentum is -3.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 5.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 56.22
- Open
- 56.05
- Day range
- 54.76 - 56.60
- Avg price
- 55.25
- Volume
- 2.08M
- Turnover
- 114.87M
- Turnover ratei
- 1.08%
- Volume ratioi
- 0.85
- Amplitudei
- 3.27%
- 52-week rangei
- 49.26 - 70.98
Valuation
- P/Ei
- 30.67
- P/E (TTM)i
- 145.26
- P/Bi
- 1.69
- EPSi
- 1.80
- Book value / shi
- 32.66
- Net profit
- 348.43M
- Net assets
- 6.32B
Share structure
- Market cap
- 10.69B
- Float capi
- 10.63B
- Shares out
- 193.57M
- Float sharesi
- 192.63M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
22.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-7.61M net over the window
Short interest
- Shares short
- 10.08M
- % of floati
- 5.21%
- Days to coveri
- 5.53
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Biomarin Pharmaceutical (BMRN)?
Biomarin Pharmaceutical last traded at 55.20. The quote on this page refreshes every few seconds while US markets are open.
What is Biomarin Pharmaceutical's market cap?
About 10.69B.
What is the P/E ratio of Biomarin Pharmaceutical?
The trailing twelve-month P/E is 145.26, below its own 5-year average of 155.81 — in the middle of its historical range (63.29% percentile). See the Valuation tab for the full history.
Does Biomarin Pharmaceutical pay a dividend?
Biomarin Pharmaceutical does not currently pay a regular dividend.
Is Biomarin Pharmaceutical a buy according to analysts?
The consensus of 21 analysts is a Buy rating, with an average 12-month price target of 94.89, which implies 71.9% upside from the current price. This is not investment advice.
What is Biomarin Pharmaceutical's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Biomarin Pharmaceutical a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 08:44:36 · For reference only, not investment advice and not tailored to your situation.